SG11201809437TA - Intracellular delivery of biomolecules to induce tolerance - Google Patents

Intracellular delivery of biomolecules to induce tolerance

Info

Publication number
SG11201809437TA
SG11201809437TA SG11201809437TA SG11201809437TA SG11201809437TA SG 11201809437T A SG11201809437T A SG 11201809437TA SG 11201809437T A SG11201809437T A SG 11201809437TA SG 11201809437T A SG11201809437T A SG 11201809437TA SG 11201809437T A SG11201809437T A SG 11201809437TA
Authority
SG
Singapore
Prior art keywords
watertown
sqz
biotechnologies
coolidge
avenue
Prior art date
Application number
SG11201809437TA
Inventor
Jonathan Gilbert
Bu Wang
Scott Loughhead
Howard Bernstein
Armon Sharei
Finola Moore
Original Assignee
Sqz Biotechnologies Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sqz Biotechnologies Co filed Critical Sqz Biotechnologies Co
Publication of SG11201809437TA publication Critical patent/SG11201809437TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M1/00—Apparatus for enzymology or microbiology
    • C12M1/12—Apparatus for enzymology or microbiology with sterilisation, filtration or dialysis means
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M23/00—Constructional details, e.g. recesses, hinges
    • C12M23/02—Form or structure of the vessel
    • C12M23/16—Microfluidic devices; Capillary tubes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M3/00—Tissue, human, animal or plant cell, or virus culture apparatus
    • C12M3/06—Tissue, human, animal or plant cell, or virus culture apparatus with filtration, ultrafiltration, inverse osmosis or dialysis means
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0641—Erythrocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0644—Platelets; Megakaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6006—Cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Transplantation (AREA)
  • Sustainable Development (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Clinical Laboratory Science (AREA)
  • Dispersion Chemistry (AREA)
  • Water Supply & Treatment (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1111111111111111111111111111111111111111111111111111111H11111111111111111111110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\"\" WO 2017/192785 Al 09 November 2017 (09.11.2017) W I P0 I P C T (51) (21) (22) (25) Filing Language: (26) (30) (71) (72) International Patent Classification: C12N 15/87 (2006.01) C12N C12M 1/00 (2006.01) A61K C12M 1/12 (2006.01) A61K C12M 3/06 (2006.01) International Application Number: International Filing Date: Publication Language: Priority Data: 62/331,368 03 May 2016 (03.05.2016) Applicant: SQZ BIOTECHNOLOGIES [US/US]; 134 Coolidge Avenue, (US). Inventors: GILBERT, Jonathan, nologies Company, 134 Coolidge 02472 (US). WANG, Bu; c/o SQZ pany, 134 Coolidge Avenue, Watertown, 03 May 2017 (03.05.2017) pany, 134 Coolidge Avenue, Watertown, MA 02472 (US). 5/078 (2010.01) SHAREI, Armon, R.; c/o SQZ Biotechnologies Compa- 39/00 (2006.01) ny, 134 Coolidge Avenue, Watertown, MA 02472 (US). 35/18 (2015.01) MOORE, Finola; c/o SQZ Biotechnologies Company, 134 Coolidge Avenue, Watertown, MA 02472 (US). (74) Agent: VANEVSKI, Filip et al.; Morrison & Foerster LLP, PCT/US2017/030932 755 Page Mill Road, Palo Alto, CA 94304-1018 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, English CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, US MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, COMPANY PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, Watertown, MA 02472 SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. B.; c/o SQZ Biotech- (84) Designated States (unless otherwise indicated, for every Avenue, Watertown, MA kind of regional protection available): ARIPO (BW, GH, Biotechnologies Com- GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, MA 02472 (US). UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, Biotechnologies Compa- TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, MA 02472 (US). EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, Biotechnologies Com- MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, = = LOUGHHEAD, Scott; c/o SQZ ny, 134 Coolidge Avenue, Watertown, BERNSTEIN, Howard; c/o SQZ _ cell Title: INTRACELLULAR DELIVERY FIG. 8 5 4 7 a' 4 C:3 gl . A 3 11 M 2 0 i 6 o OF a BIOMOLECULES TO INDUCE Spleen *x-ar* TOLERANCE Lymph Nodes l x;, l< = (54) = — = = __ T g ri 23 = el V'r 15 = n n ice. , Q I— 0 , 0 ,, a eu a'. = 4 Vf. - -4 , _ _ . 4 z •ca a\" b° & Cr CI 4r§' \" g- 4, and/or suppressing an immune response to an antigen wherein the constriction deforms the cell thereby enters the cell. In some embodiments, the anucleate in a tolerogenic environment to induce tolerance and/ _ passing suppress ,.. t z s e ,6 CP ( 46 \" : The present invention provides methods for inducing tolerance a cell suspension containing an anucleate cell through a constriction, a perturbation of the cell such that an antigen and/or tolerogenic factor is delivered to an individual and the antigen is delivered to and processed an immune response to the antigen. 1 ir) GC IN ei (57) 01 by 1-1 ---- causing IN C:0) or ei C [Continued on next page] WO 2017/192785 Al III V TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
SG11201809437TA 2016-05-03 2017-05-03 Intracellular delivery of biomolecules to induce tolerance SG11201809437TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662331368P 2016-05-03 2016-05-03
PCT/US2017/030932 WO2017192785A1 (en) 2016-05-03 2017-05-03 Intracellular delivery of biomolecules to induce tolerance

Publications (1)

Publication Number Publication Date
SG11201809437TA true SG11201809437TA (en) 2018-11-29

Family

ID=58993188

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201809437TA SG11201809437TA (en) 2016-05-03 2017-05-03 Intracellular delivery of biomolecules to induce tolerance

Country Status (11)

Country Link
US (1) US20190111082A1 (en)
EP (1) EP3452604A1 (en)
JP (2) JP2019519483A (en)
KR (1) KR102430856B1 (en)
CN (1) CN109415741A (en)
AU (1) AU2017259987B2 (en)
CA (1) CA3023092A1 (en)
IL (1) IL262677A (en)
RU (1) RU2770492C2 (en)
SG (1) SG11201809437TA (en)
WO (1) WO2017192785A1 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
CN108117586A (en) 2010-08-10 2018-06-05 洛桑聚合联合学院 Erythrocyte binding therapeutic agent
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
RS59898B1 (en) 2011-10-17 2020-03-31 Massachusetts Inst Technology Intracellular delivery
AU2014306423B2 (en) 2013-08-16 2019-04-18 Massachusetts Institute Of Technology Selective delivery of material to cells
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
JP6744227B2 (en) 2014-02-21 2020-08-19 エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ（ウペエフエル）Ｅｃｏｌｅ Ｐｏｌｙｔｅｃｈｎｉｑｕｅ Ｆｅｄｅｒａｌｅ ｄｅ Ｌａｕｓａｎｎｅ （ＥＰＦＬ） Sugar-targeted therapeutic agent
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
CN107109362A (en) 2014-10-31 2017-08-29 麻省理工学院 Biomolecule is delivered to immunocyte
US10526573B2 (en) 2014-11-14 2020-01-07 Massachusetts Institute Of Technology Disruption and field enabled delivery of compounds and compositions into cells
JP7278027B2 (en) 2015-01-12 2023-05-19 マサチューセッツ インスティテュート オブ テクノロジー Gene editing by microfluidic delivery
EP3320082B1 (en) 2015-07-09 2023-05-24 Massachusetts Institute of Technology Delivery of materials to anucleate cells
US11613759B2 (en) 2015-09-04 2023-03-28 Sqz Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall
WO2018232176A1 (en) 2017-06-16 2018-12-20 The University Of Chicago Compositions and methods for inducing immune tolerance
WO2019126146A1 (en) 2017-12-19 2019-06-27 Xcell Biosciences, Inc. Methods of modulating cell phenotype by way of regulating the gaseous environment
KR20210121106A (en) * 2019-01-25 2021-10-07 에스큐지 바이오테크놀로지스 컴퍼니 Non-nucleated cell-derived vaccines
AU2020228648A1 (en) 2019-02-28 2021-10-14 Sqz Biotechnologies Company Delivery of biomolecules to PBMCs to modify an immune response
US11679388B2 (en) 2019-04-08 2023-06-20 Sqz Biotechnologies Company Cartridge for use in a system for delivery of a payload into a cell
TW202207975A (en) 2020-05-11 2022-03-01 瑞士商赫孚孟拉羅股份公司 Combination therapy with modified pbmcs and an immunoconjugate
WO2022026620A1 (en) 2020-07-29 2022-02-03 Sqz Biotechnologies Company Methods to stimulate immune responses to mutant ras using nucleated cells
CN116322752A (en) 2020-07-29 2023-06-23 Sqz生物技术公司 Methods of stimulating immune responses to mutant RAS using anuclear cells
IL302976A (en) 2020-11-18 2023-07-01 Cellfe Inc Methods and systems for mechanoporation-based payload delivery into biological cells
EP4271793A1 (en) 2020-12-29 2023-11-08 SQZ Biotechnologies Company Microfluidic chip having increased throughput for use in a system for delivery of a payload into a cell
US20220233677A1 (en) 2020-12-29 2022-07-28 Sqz Biotechnologies Company Methods for treating cancers with modified pbmcs
CN116801719A (en) 2020-12-29 2023-09-22 Sqz生物技术公司 Formulations for cryopreservation of PBMC
CA3203356A1 (en) 2020-12-29 2022-07-07 Oliver Rosen Methods for treating cancers with activating antigen carriers
CN116847880A (en) 2020-12-29 2023-10-03 Sqz生物技术公司 Formulation for activating antigen carriers
WO2023010090A1 (en) 2021-07-29 2023-02-02 Sqz Biotechnologies Company Methods to generate enhanced tumor infiltrating lymphocytes through microfluidic delivery
WO2023087009A1 (en) 2021-11-11 2023-05-19 Sqz Biotechnologies Company Methods to generate enhanced tumor infiltrating lymphocytes through microfluidic delivery
WO2024026491A2 (en) 2022-07-28 2024-02-01 Sqz Biotechnologies Company Enhanced antigen presenting cell formulations
WO2024026492A1 (en) 2022-07-28 2024-02-01 Sqz Biotechnologies Company Methods for treating cancer with enhanced antigen presenting cells

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995015982A2 (en) * 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
KR20060040671A (en) * 2003-07-11 2006-05-10 블라스티콘 바이오테크놀로지셰 포르슝 게엠베하 Autologous self-tolerance inducing cells of monocytic origin and their use in pharmaceutical preparations
US20120207745A1 (en) * 2009-10-27 2012-08-16 Yann Godfrin Composition to Induce Specific Immune Tolerance
CN108117586A (en) 2010-08-10 2018-06-05 洛桑聚合联合学院 Erythrocyte binding therapeutic agent
RS59898B1 (en) * 2011-10-17 2020-03-31 Massachusetts Inst Technology Intracellular delivery
ES2781773T3 (en) 2012-02-15 2020-09-07 Ecole Polytechnique Fed Lausanne Epfl Erythrocyte binding therapeutics
AU2014306423B2 (en) 2013-08-16 2019-04-18 Massachusetts Institute Of Technology Selective delivery of material to cells
KR101613675B1 (en) * 2013-11-15 2016-04-20 차의과학대학교 산학협력단 Method for preparing a immune tolerant dendritic cell and the immune tolerant dendritic cell prepared by the method
CN107109362A (en) 2014-10-31 2017-08-29 麻省理工学院 Biomolecule is delivered to immunocyte
US10526573B2 (en) 2014-11-14 2020-01-07 Massachusetts Institute Of Technology Disruption and field enabled delivery of compounds and compositions into cells
EP3320082B1 (en) * 2015-07-09 2023-05-24 Massachusetts Institute of Technology Delivery of materials to anucleate cells

Also Published As

Publication number Publication date
EP3452604A1 (en) 2019-03-13
RU2018142317A (en) 2020-06-03
RU2770492C2 (en) 2022-04-18
AU2017259987A1 (en) 2018-11-22
KR102430856B1 (en) 2022-08-08
KR20190003735A (en) 2019-01-09
US20190111082A1 (en) 2019-04-18
AU2017259987B2 (en) 2023-10-19
JP2021176904A (en) 2021-11-11
JP2019519483A (en) 2019-07-11
IL262677A (en) 2018-12-31
RU2018142317A3 (en) 2020-10-16
CN109415741A (en) 2019-03-01
CA3023092A1 (en) 2017-11-09
WO2017192785A1 (en) 2017-11-09

Similar Documents

Publication Publication Date Title
SG11201809437TA (en) Intracellular delivery of biomolecules to induce tolerance
SG11201808990QA (en) Compositions for topical application of compounds
SG11201909949XA (en) Targeted immunotolerance
SG11201901531TA (en) Regulation of gene expression using engineered nucleases
SG11201908478SA (en) Sterilisation method
SG11201803983UA (en) Transformable tagging compositions, methods, and processes incorporating same
SG11201808196UA (en) Neoantigens and methods of their use
SG11201901642XA (en) Constitutively active cytokine receptors for cell therapy
SG11201807573VA (en) Methods for providing single-stranded rna
SG11201909011PA (en) Niraparib compositions
SG11201909868YA (en) Compositions and methods of treating huntington&#39;s disease
SG11201901364VA (en) Engineered target specific nucleases
SG11201810179RA (en) Novel crispr enzymes and systems
SG11201908527SA (en) High affinity mage-a1-specific tcrs and uses thereof
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201804443UA (en) Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome
SG11201909931PA (en) Oligomeric particle reagents and methods of use thereof
SG11201805072PA (en) Nicotine powder delivery system
SG11201906301UA (en) Methods of manufacture of nut flours and formulations for oral immunotherapy
SG11201903456WA (en) Piperidine derivatives as inhibitors of ubiquitin specific protease 7
SG11201808528VA (en) Modified wound dressings
SG11201901020RA (en) Anti-siglec-7 antibodies for the treatment of cancer
SG11201808215SA (en) Aluminum alloys having iron, silicon, vanadium and copper, and with a high volume of ceramic phase therein
SG11201906717SA (en) Methods and systems for associating physical and genetic properties of biological particles
SG11201809497RA (en) Processes for preparing phosphorodiamidate morpholino oligomers